Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Six-Factor Stratification Approach for Enfortumab Vedotin Treatment in Previously Treated Patients with Advanced Urothelial Carcinoma

  • By

  • Yuto Matsushita

  • Satoru Taguchi

  • Taku Naiki

  • Gaku Ishikawa

  • Yu Nakamura

  • Jimpei Miyakawa

  • Takashi Nagai

  • Tomoyuki Kaneko

  • Hiroki Kubota

  • Hayato Hoshina

  • Jun Kamei

  • Aya Niimi

  • Yuta Yamada

  • Daisuke Obinata

  • Shigenori Kakutani

  • Masashi Shiozaki

  • Kento Ozawa

  • Michio Noda

  • Daichi Hirata

  • Yuichi Kitagawa

  • Yukihiro Yoshimi

  • Nozomi Sugiyama

  • Nobuhiko Shimizu

  • Yohei Tsubouchi

  • Keigo Sato

  • Kosuke Uchida

  • Shinya Watanabe

  • Jun Takahashi

  • Toshiharu Morikawa

  • Yoichi Mori

  • Takashi Murata

  • Taro Murata

  • Taketo Kawai

  • Takehiro Tanaka

  • Yukari Uemura

  • Tappei Takada

  • Sayuri Takahashi

  • Toshiki Ito

  • Masao Nagata

  • Hideyo Miyazaki

  • Satoshi Kurokawa

  • Yukio Yamada

  • Ryo Sato

  • Atsushi Otsuka

  • Yusuke Sato

  • Hiroaki Nishimatsu

  • Yukihiro Umemoto

  • Hiroshi Furuse

  • Yoshiyuki Akiyama

  • Yutaka Enomoto

  • Satoru Takahashi

  • Tetsuya Fujimura

  • Tohru Nakagawa

  • Hiroshi Fukuhara

  • Takahiro Yasui

  • Haruki Kume

  • Teruo Inamoto

  • September 11, 2026

Share

  • 1

    The EV-301 trial demonstrated that enfortumab vedotin (EV) monotherapy offers oncological benefits over standard chemotherapy for advanced urothelial carcinoma.

  • 2

    A multicenter retrospective study analyzed 482 patients with advanced urothelial carcinoma treated with EV monotherapy to identify prognostic factors.

  • 3

    The study identified six common poor prognostic factors for progression-free survival and overall survival: poor ECOG performance status, aberrant histology, and others.

  • 4

    Median progression-free survival was 7.6 months, while median overall survival was 14.6 months among the 387 patients evaluated in the study.

  • 5

    The study's findings contribute to the understanding of prognostic risk factors, aiding in the stratification of patients receiving EV treatment.

Original Source(s)

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma

  • by Yuto Matsushita, Satoru Taguchi, Taku Naiki, Gaku Ishikawa, Yu Nakamura, Jimpei Miyakawa, Takashi Nagai, Tomoyuki Kaneko, Hiroki Kubota, Hayato Hoshina, Jun Kamei, Aya Niimi, Yuta Yamada, Daisuke Obinata, Shigenori Kakutani, Masashi Shiozaki, Kento Ozawa, Michio Noda, Daichi Hirata, Yuichi Kitagawa, Yukihiro Yoshimi, Nozomi Sugiyama, Nobuhiko Shimizu, Yohei Tsubouchi, Keigo Sato, Kosuke Uchida, Shinya Watanabe, Jun Takahashi, Toshiharu Morikawa, Yoichi Mori, Takashi Murata, Taro Murata, Taketo Kawai, Takehiro Tanaka, Yukari Uemura, Tappei Takada, Sayuri Takahashi, Toshiki Ito, Masao Nagata, Hideyo Miyazaki, Satoshi Kurokawa, Yukio Yamada, Ryo Sato, Atsushi Otsuka, Yusuke Sato, Hiroaki Nishimatsu, Yukihiro Umemoto, Hiroshi Furuse, Yoshiyuki Akiyama, Yutaka Enomoto, Satoru Takahashi, Tetsuya Fujimura, Tohru Nakagawa, Hiroshi Fukuhara, Takahiro Yasui, Haruki Kume, Teruo Inamoto

  • September 11, 2026

Related Content

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

Case Report: Donor-derived early T-cell precursor acute lymphoblastic leukemia following an allogeneic hematopoietic stem cell transplantation for pediatric severe aplastic anemia